

How to Navigate the Future Parallel HTA and EMA Processes in the EU

23 March 2026 | 11:00-18:00 CET | Rotterdam, NL



Overview

The first Joint Clinical Assessment (JCA) submissions under the HTA Regulation are underway. For new cancer medicines and ATMPs, since January 2025 the Regulatory submissions through the centralised procedure to the European Medicines Agency (EMA) will also trigger the JCA process. Both processes will run in parallel and the new legislative framework for exchange of information between regulators and HTA will take effect. The new process will require a close collaboration between the regulatory and HTA/market access teams at company level.

This course will discuss regulatory preparedness for the JCA process, explain the interface between regulators and EU HTA Coordination Group and which information is shared by the two.

It will inform you about practical strategic and operational challenges and how to solve them. Preparation early on in development is key, hence two workshops in small groups will focus on the role of prospective evidence planning/Joint Scientific consultation and the operational aspects of writing and submitting the JCA dossier.

The instructors have been very close to the HTA Regulation implementation activities in companies and with the policymakers.

Learning Objectives

- Understand the JCA process and how it links to the marketing authorisation process
- Regulatory documents or information shared to inform scoping process and JCA timelines
- Reducing the risk of the regulatory process to impact the JCA process
- Preparing and aligning internally
- Understand the role of prospective evidence planning/Joint Scientific consultation
- The operational aspects of writing and submitting the JCA dossier

Who Will Attend

- Regulatory strategy leads
- Regulatory authority members
- Clinical development professionals
- CROs
- Consultants involved in EMA's approval processes

Faculty

Thomas Ecker

CEO
Ecker + Ecker

Inka Heikkinen

Regulatory Policy Lead
Lundbeck

Nadege Le Roux

Regulatory Policy Senior Director
Bristol Myers Squibb

Isabelle Stoeckert

Independent Regulatory Science Expert

Anke van Engen

Global Category Leader, Health Economics,
HTA, Value and Access
IQVIA

Schedule-At-A-Glance

10:30 REGISTRATION

11:00 WELCOME AND INTRODUCTION

11:15 SESSION 1 PART 1

JCA LEGISLATIVE FRAMEWORK AND GUIDELINES

Inka Heikkinen

- Introduction to HTA Regulation and implementing acts
- The HTA JCA process and how it relates to EU Marketing Authorisation Application process
- Rules for exchange of information between the EMA and EU HTA Coordination Group, and its subgroups

12:00 SESSION 1 PART 2

JSC FRAMEWORK AND PROCESS

Inka Heikkinen

- JSC regulatory framework
- Application process and tips for the application form
- Learnings from previous parallel advice

12:30 SESSION 2

IMPLICATIONS FOR REGULATORY STRATEGY AND ENGAGEMENT PLAN

Isabelle Stoeckert

- Regulatory relevant aspect of the JCA dossier (PICO concept and dossier content)
- Label considerations and scenario planning
- Narrative alignment and managing the parallel process
- Transparency of the JCA dossier and potential implications

13:15 LUNCH BREAK

14:00 SESSION 3

INTERNAL ALIGNMENT AND COMMUNICATION AS THE CORNERSTONE FOR SUCCESS

Nadege Le Roux

- Reducing uncertainties through close communication of timelines, anticipated questions and final indication

14:45 SESSION 4

JCA DOSSIER - WHAT GOES IN IT?

Thomas Ecker

- Specifications of the JCA dossier
- Similarities with the AMNOG dossier
- Common and different elements to the regulatory dossier
- Guidances

15:30 SESSION 5

EVIDENCE GENERATION - ADDRESSING THE POSSIBLE GAPS

Anke van Engen

- Learnings from the PICO simulations & required evidence
- Overview of non-direct evidence approaches and acceptable methods

16:15 COFFEE BREAK

16:30 SESSION 6

GROUP DISCUSSIONS

Participants will discuss one topic for 30 min, then switch the group to discuss the other topic for 30 min

- Group A: JCA DOSSIER AND PICO ANTICIPATION
Moderation: Thomas Ecker and Inka Heikkinen
- Group B: EVIDENCE GENERATION AND ADVICE
Moderation: Anke van Engen and Nadege Le Roux

17:30 CLOSING OF THE COURSE

- Recap from the discussions
- Contribute to a learning system
- Outlook on future development - what can be expected from the policymakers?
- Remaining questions

18:00 END OF THE TRAINING COURSE

Unless otherwise disclosed, DIA acknowledges that the statements made by speakers are their own opinion and not necessarily that of the organisation they represent, or that of the DIA. Speakers and agenda are subject to change without notice. Recording during DIA sessions is strictly prohibited without prior written consent from DIA.



Group Discounts

Register 3 individuals from the same company for the same course and receive complimentary registration for a 4th!*

To take advantage of this offer, please print the registration form for EACH of the four registrants from your company. Include the names of all four group registrants on each of the forms and return them together via email to basel@diaglobal.org.

**Terms and Conditions apply. Please contact DIA EMEA office for more information.*



About DIA

DIA is the global connector in the life sciences product development process. Our association of more than 18,000 members builds productive relationships by bringing together regulators, innovators, and influencers to exchange knowledge and collaborate in an impartial setting. DIA's network creates unparalleled opportunities for exchange of knowledge and has the inter-disciplinary experience to prepare for future developments.

The dedicated efforts of DIA staff, members and speakers enable DIA to provide a comprehensive catalogue of conferences, workshops, training courses, scientific publications and educational materials. DIA is a global community representing thousands of stakeholders working together to bring safe and effective products to patients.

DIA is an independent, non-profit organisation has its Global Center in Washington, DC, USA with the European office in Basel, Switzerland, and additional regional offices in Horsham, Pennsylvania, USA; Tokyo, Japan; Mumbai, India; and Beijing, China



Venue Information

Rotterdam Ahoy

Ahoyweg 10, 3084 BA Rotterdam, NL

Hotel Booking

For more information, please visit: <https://www.diaglobal.org/en/flagship/dia-europe-2026/hotel-and-travel/hotel>

How to get there

Rotterdam is easily accessible from various international destinations. Travelers can fly into Schiphol International Airport in Amsterdam, which is about 26 minutes away by high-speed train. Alternatively, Rotterdam The Hague Airport offers direct flights from many European cities and is just a 15-minute drive to the city center. For those coming from nearby countries like Belgium or France, the Eurostar provides a convenient train connection to Rotterdam.



Continuing Education

All DIA training courses have been awarded a PharmaTrain Centre Recognition.

PharmaTrain Federation is a not for profit organisation that started its activities as an IMI (Innovative Medicines Initiative) European Project. Its mission is to drive implementation of globally recognized high-level standards for postgraduate education and training in Medicines Development. To that aim, the Federation is assessing Continuous Professional Development (CPD) Courses and Course Providers around the world that deserve recognition.



REGISTRATION FORM

How to Navigate the HTA and EMA Processes # 26590

23 March 2026 | 11:00-18:00 CET | Rotterdam, NL

REGISTRATION FEES

Registration fee includes admission to training course, refreshment breaks and electronic access to training course materials.

Please note that the full amount must be received by DIA by commencement of the course to get the electronic access to the material. Please check:

FEES	MEMBER EARLY-BIRD valid until 26 Jan 2026	MEMBER valid from 27 Jan 2026	NON-MEMBER
INDUSTRY/ REPRESENTATIVE	€ 720.00 <input type="checkbox"/>	€ 800.00 <input type="checkbox"/>	€ 1'060.00 <input type="checkbox"/>
ACADEMIA/CHARITABLE/GOVERNMENT/NON-PROFIT (FULL-TIME)	NA	€ 400.00 <input type="checkbox"/>	€ 660.00 <input type="checkbox"/>
<p><u>A special discount is available for organisations which are listed in the EMA SME register:</u> https://fmapps.ema.europa.eu/SME/. Number of discounted seats is limited.</p>			

All registration fees are subject to VAT if applicable.

Please enter your company's VAT number: _____

If DIA cannot verify your membership upon receipt of registration form, you will be charged the non-member fee.

DIA MEMBERSHIP

All nonmember fees include a one year DIA membership, at no additional cost. Explore membership benefits at DiAglobal.org/Membership.

DIA membership will renew automatically at the end of the complimentary membership term, at the then current membership rates. You may cancel automatic membership renewal at any time by accessing your account online at DiAglobal.org. If you would like to decline complimentary membership, please indicate your preference below.

I would like to decline a one year complimentary DIA membership.

The DIA Contact Centre Team will be pleased to assist you with your registration from Monday to Friday between 09:00 and 17:00 CE(S)T. **Tel.** :+41 61 225 51 51

Email: Basel@DiAglobal.org **Mail:** DIA, Küchengasse 16, 4051 Basel, Switzerland

Web: www.DiAglobal.org

ATTENDEE DETAILS

Please complete in block capital letters or attach the attendee's business card here.

Prof Dr Ms Mr

Last Name

First Name

Job Title

Company

Address

Postal Code

City

Country

Telephone Number

Attendee email required for course material access

PAYMENT METHOD

DIA accepts only Credit Card as a payment method.

Payments by VISA, Mastercard or AMEX are accepted. Other types of credit card are not accepted.

You will receive a payment link in the coming days to complete the payment.

Please complete payment within 7 days of receipt of the payment link.

Payments will be net of all charges and bank charges will be borne by the payer.

If you have not received your confirmation within five working days, please contact basel@diaglobal.org.

By signing below, I confirm that I read and agree with DIA's Terms and Conditions of booking.

These are available from the office or online by clicking:

<http://www.diaglobal.org/EUterms>

Date	Signature
------	-----------